Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia.

Park JS, Kwon J, Choi HJ, Lee C

Medicine1 Jan 2021Cited by 25 (Europe PMC)

PMID33466127PMCIDPMC7808520DOI10.1097/md.0000000000023780PepBankPUB-33466127

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In obese South Korean patients (BMI above 27) treated with liraglutide, body weight fell significantly during follow-up.
In plain wordsIn obese patients in South Korea, body weight fell during liraglutide treatment. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseBody weight reduction
Study
n = 169
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 to 180 daysAs given in this study (human).
Measurements
Weight change
−5.5 kg
overall
Weight change
−3.2 kg
30 days
Weight change
−4.5 kg
60 days
Weight change
−6.3 kg
90 days
Weight change
−7.8 kg
180 days
Source sentences
Summary
Weight reduction was significant (-5.5 ± 3.4 kg, 30 days: -3.2 ± 1.8 kg, 60 days: -4.5 ± 2.3 kg, 90 days: -6.3 ± 2.6 kg, 180 days: -7.8 ± 3.5 kg) during the follow-up period and increased with longer treatment time (P < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic.
Report a problemFND-3346612701
02HumanObservational studyEfficacy outcome
In obese South Korean patients treated with liraglutide, weight reduction increased with longer treatment time.
In plain wordsIn obese patients in South Korea, the longer liraglutide was used, the more weight was lost. There was no placebo group.
Peptide
Liraglutide
Outcome
IncreaseWeight reduction by treatment time
Study
n = 169
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 to 180 daysAs given in this study (human).
Source sentences
Summary
and increased with longer treatment time (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic.
Report a problemFND-3346612702
03HumanObservational studyEfficacy outcome
In obese South Korean patients treated with liraglutide, 62.1% had a body weight reduction of 5% or more.
In plain wordsIn obese patients in South Korea using liraglutide, 62.1% lost at least 5% of body weight.
Peptide
Liraglutide
Outcome
Not applicableProportion with at least 5% weight reduction
Study
n = 169
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 to 180 daysAs given in this study (human).
Measurements
Responders at least 5% weight loss
62.1%
all subjects
Source sentences
Summary
The percentages of subjects that showed ≥ 5% and ≥ 10% body weight reduction were 62.1% and 17.2%, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic.
Report a problemFND-3346612703
04HumanObservational studyEfficacy outcome
In obese South Korean patients treated with liraglutide, 17.2% had a body weight reduction of 10% or more.
In plain wordsIn obese patients in South Korea using liraglutide, 17.2% lost at least 10% of body weight.
Peptide
Liraglutide
Outcome
Not applicableProportion with at least 10% weight reduction
Study
n = 169
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 to 180 daysAs given in this study (human).
Measurements
Responders at least 10% weight loss
17.2%
all subjects
Source sentences
Summary
The percentages of subjects that showed ≥ 5% and ≥ 10% body weight reduction were 62.1% and 17.2%, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic.
Report a problemFND-3346612704
05HumanObservational studyEfficacy outcome
In obese South Korean patients treated with liraglutide, fat weight fell by 11.06%, significantly more than skeletal muscle weight.
In plain wordsIn obese patients in South Korea using liraglutide, fat mass fell more than muscle mass. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseFat weight loss
Study
n = 169
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 to 180 daysAs given in this study (human).
Measurements
Fat weight change
−11.06%
body composition analysis
Source sentences
Summary
In the body composition analysis, skeletal muscle weight loss was -3.56 ± 29.7%, which was significantly smaller than fat weight loss of -11.06 ± 10.4% (P = .03).
1 context sentence(design, population, supporting numbers)
Summary · context
Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic.
Report a problemFND-3346612705
06HumanObservational studyEfficacy outcome
In obese South Korean patients treated with liraglutide, skeletal muscle weight fell by 3.56%, significantly less than fat weight.
In plain wordsIn obese patients in South Korea using liraglutide, muscle mass fell less than fat mass. There was no placebo group.
Peptide
Liraglutide
Outcome
DecreaseSkeletal muscle weight loss
Study
n = 169
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 to 180 daysAs given in this study (human).
Measurements
Skeletal muscle weight change
−3.56%
body composition analysis
Source sentences
Summary
In the body composition analysis, skeletal muscle weight loss was -3.56 ± 29.7%, which was significantly smaller than fat weight loss of -11.06 ± 10.4% (P = .03).
1 context sentence(design, population, supporting numbers)
Summary · context
Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic.
Report a problemFND-3346612706
07HumanObservational studyOther
In obese South Korean patients treated with liraglutide, weight loss was not significantly related to age, sex, baseline BMI, baseline HbA1c, smoking, alcohol or coffee intake.
In plain wordsIn obese patients in South Korea using liraglutide, weight loss was not clearly linked to age, sex, starting BMI or lifestyle habits.
Peptide
Liraglutide
Outcome
No significant changeAssociation of weight loss with patient characteristics
Study
n = 169
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 to 180 daysAs given in this study (human).
Source sentences
Summary
Weight loss was not significantly related to age, sex, baseline BMI, baseline HbA1c, smoking status, alcohol consumption, coffee intake
1 context sentence(design, population, supporting numbers)
Summary · context
Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations.In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic.
Report a problemFND-3346612707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.